CN103705537A - Applications of hydrogen sulfide and donor thereof sodium hydrosulfide in preparation of medicines used for treating lipid metabolism disorders - Google Patents
Applications of hydrogen sulfide and donor thereof sodium hydrosulfide in preparation of medicines used for treating lipid metabolism disorders Download PDFInfo
- Publication number
- CN103705537A CN103705537A CN201210378597.4A CN201210378597A CN103705537A CN 103705537 A CN103705537 A CN 103705537A CN 201210378597 A CN201210378597 A CN 201210378597A CN 103705537 A CN103705537 A CN 103705537A
- Authority
- CN
- China
- Prior art keywords
- hydrogen sulfide
- sodium hydrosulfide
- donor
- preparation
- lipid metabolism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention belongs to the medicine and pharmaceutical field, and relates to applications of hydrogen sulfide and a donor thereof sodium hydrosulfide in preparation of medicines used for treating lipid metabolism disorders. Animal experiments slowly administrating NaHS are adopted. Results show that plasma cholesterol and blood pressure of GK diabetic rats and of Wistar rats can be lowered by slowly administrating the NaHS. The results show that the hydrogen sulfide and the donor thereof sodium hydrosulfide have a certain adjusting function for 2-type diabetes accompanied with the lipid metabolism disorders and that the hydrogen sulfide and the donor thereof sodium hydrosulfide can improve the abnormal liver function. The hydrogen sulfide and the donor thereof sodium hydrosulfide can improve the lipid metabolism disorders and fatty liver in the metabolic syndrome, reduce generation of liver injury, and can be used for preparation of medicines treating the lipid metabolism disorders. The hydrogen sulfide and the donor thereof sodium hydrosulfide can be used for preparation of medicines treating hyperlipoprotememia, hypertriglyceridemia, high cholesterol, fatty liver and adiposity, and medicines for preventing liver injury caused by the lipid metabolism disorders.
Description
Technical field
The invention belongs to medicine pharmaceutical field, relate to hydrogen sulfide and donor sodium hydrosulfide thereof new pharmaceutical usage in pharmacy, relate in particular to hydrogen sulfide and donor sodium hydrosulfide thereof the purposes in preparation treatment lipid metabolic disorder medicine.
Background technology
Prior art discloses hydrogen sulfide (H
2s) be the metabolite of cysteine in human body, its content in human body is very low is about 20～50 μ mol/L, and is difficult for manual control, and document is also reported H
2s is a kind of novel endogenous gas molecule that participates in cardiovascular activity, has the purposes that promotes cardiovascular disease angiogenesis.
Statistics report, at present, diabetes are 1-2% at population of China sickness rate, can be up to 12% in old people.The diabetes diagnosis standard of revising according to international diabetologist committee, diagnosis standards of fasting plasma glucose is >=126mg/ml, the sickness rate of diabetes is ascendant trend year by year, and the patient of type 2 diabetes mellitus (great majority are senile diabetes) significantly increases, and to the harm of human health, also will be larger.Studies show that, in type 2 diabetes mellitus patient, disorders of lipid metabolism is commonplace, and main manifestations is that hypertriglyceridemia, high density lipoprotein reduce, low density lipoprotein, LDL increases; And hyperglycemia, hyperlipidemia will cause diabetic complication as the generation of atherosclerosis, fatty liver etc. for a long time, therefore, in research diabetics, disorders of lipid metabolism has important clinical meaning.
Summary of the invention
Object of the present invention is to provide hydrogen sulfide (H
2s) and the new purposes of donor sodium hydrosulfide (NaHS) in pharmacy.Relate in particular to hydrogen sulfide and donor sodium hydrosulfide thereof the purposes in preparation treatment lipid metabolic disorder medicine.
The present invention has carried out the chronic NaHS zoopery that gives, result demonstration, and the chronic NaHS of giving can reduce plasma cholesterol and the blood pressure of GK diabetes rat and Wistar rat, gives the NaHS of GK rat variable concentrations after six weeks, NaHS30 μ molkg
-1day
-1the high density lipoprotein of group increases, and fasting glucose, T-CHOL, low density lipoprotein, LDL and blood pressure all reduce; NaHS 60 μ molkg
-1day
-1group T-CHOL and Blood pressure drop; NaHS 120 μ molkg
-1day
-1group is only observed high density lipoprotein increases (as shown in table 1) to some extent;
Give the NaHS of Wistar rat variable concentrations after six weeks, NaHS 30 μ molkg
-1day
-1the high density lipoprotein of group increases, and fasting glucose, T-CHOL and triglyceride all reduce; NaHS 60 μ molkg
-1day
-1fasting glucose reduces; NaHS 120 μ molkg
-1day
-1group is observed high density lipoprotein increases (as shown in table 2) to some extent;
Experimental result shows, hydrogen sulfide and donor sodium hydrosulfide thereof merge disorders of lipid metabolism to type 2 diabetes mellitus obvious regulating action, can improve the abnormal of liver function.
Hydrogen sulfide of the present invention and donor sodium hydrosulfide thereof can be used for the medicine of preparation treatment lipid metabolic disorder, and described lipid metabolic disorder is generally hyperlipoproteinemia, hypertriglyceridemia, hypercholesterolemia, fatty liver and obesity; Meanwhile, described hydrogen sulfide and donor sodium hydrosulfide thereof can improve disorders of lipid metabolism and the fatty liver in metabolic syndrome, thus the generation that contributes to alleviate hepar damnification.
Table 1 is that GK rat is processed six weeks blood biochemistry and hematodinamics indexs afterwards with NaHS.
Table 2 is that Wistar rat is processed six weeks rear blood biochemistry index with NaHS.
Table 1
With matched group comparison, * P<0.05 difference has statistical significance;
Table 2
With matched group comparison, * P<0.05 difference has statistical significance;
Hydrogen sulfide of the present invention and donor sodium hydrosulfide thereof also can be used for the medicine of preparation treatment hyperlipoproteinemia, and for the preparation of the medicine for the treatment of hypertriglyceridemia, the medicine of the medicine for the treatment of high-cholesterol disease, the treatment medicine of fatty liver, the medicine for the treatment of of obesity, the hepar damnification that causes of prevention lipid metabolic disorder, wherein, the hepar damnification that described lipid metabolic disorder causes is the liver complication that lipid metabolic disorder causes.
The specific embodiment
Embodiment 1
Select GK rat as the chronic NaHS animal model that gives of the present embodiment, adopt conventional method to detect GK rat and process blood biochemistry and hematodinamics index after six weeks with NaHS, result shows, gives the NaHS of GK rat variable concentrations after six weeks, NaHS 30 μ molkg
-1day
-1the high density lipoprotein of group increases, and fasting glucose, T-CHOL, low density lipoprotein, LDL and blood pressure all reduce; NaHS 60 μ molkg
-1day
-1group T-CHOL and Blood pressure drop; NaHS 120 μ molkg
-1day
-1group is only observed high density lipoprotein increases (as shown in table 1) to some extent.
Table 1.GK rat is processed six weeks blood biochemistry and hematodinamics indexs afterwards with NaHS
With matched group comparison, * P<0.05 difference has statistical significance;
Embodiment 2
The chronic NaHS variable concentrations (30,60 and 120 μ mol/L) that gives, after six weeks, is observed the blood biochemistry index of Wistar rat according to a conventional method, and result shows, gives the NaHS of Wistar rat variable concentrations after six weeks, NaHS 30 μ molkg
-1day
-1the high density lipoprotein of group increases, and fasting glucose, T-CHOL and triglyceride all reduce; NaHS 60 μ molkg
-1day
-1fasting glucose reduces; NaHS 120 μ molkg
-1day
-1group is observed high density lipoprotein increases (as shown in table 2) to some extent.
Table 2.Wistar rat is processed six weeks rear blood biochemistry index with NaHS
With matched group comparison, * P<0.05 difference has statistical significance.
Claims (10)
1. hydrogen sulfide and donor sodium hydrosulfide thereof are treated the purposes in lipid metabolic disorder medicine in preparation.
2. by purposes claimed in claim 1, wherein said lipid metabolic disorder is hyperlipoproteinemia, hypertriglyceridemia, hypercholesterolemia, fatty liver and obesity.
3. by the purposes described in claim 1 or 2, wherein hydrogen sulfide and donor sodium hydrosulfide thereof are for improving disorders of lipid metabolism and the fatty liver of metabolic syndrome, the generation that alleviates hepar damnification.
4. hydrogen sulfide and donor sodium hydrosulfide thereof are treated the purposes in teinemia disease drug in preparation.
5. hydrogen sulfide and donor sodium hydrosulfide thereof are treated the purposes in hypertriglyceridemia medicine in preparation.
6. hydrogen sulfide and donor sodium hydrosulfide thereof are treated the purposes in hypercholesterolemia disease drug in preparation.
7. hydrogen sulfide and donor sodium hydrosulfide thereof are treated the purposes in fatty liver medicine in preparation.
8. hydrogen sulfide and donor sodium hydrosulfide thereof the purposes in preparing obesity treating medicine.
9. the purposes in the hepar damnification medicine that hydrogen sulfide and donor sodium hydrosulfide thereof cause at preparation prevention lipid metabolic disorder.
10. by purposes claimed in claim 9, the hepar damnification that wherein said lipid metabolic disorder causes is the liver complication that lipid metabolic disorder causes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210378597.4A CN103705537A (en) | 2012-09-29 | 2012-09-29 | Applications of hydrogen sulfide and donor thereof sodium hydrosulfide in preparation of medicines used for treating lipid metabolism disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210378597.4A CN103705537A (en) | 2012-09-29 | 2012-09-29 | Applications of hydrogen sulfide and donor thereof sodium hydrosulfide in preparation of medicines used for treating lipid metabolism disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103705537A true CN103705537A (en) | 2014-04-09 |
Family
ID=50399124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210378597.4A Pending CN103705537A (en) | 2012-09-29 | 2012-09-29 | Applications of hydrogen sulfide and donor thereof sodium hydrosulfide in preparation of medicines used for treating lipid metabolism disorders |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103705537A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106176801A (en) * | 2015-05-06 | 2016-12-07 | 复旦大学 | Hydrogen sulfide purposes in struvite anemia medicine is treated in preparation |
| CN106539818A (en) * | 2015-09-20 | 2017-03-29 | 复旦大学 | Hydrogen sulfide and its donor sodium hydrosulfide are preparing the purposes promoted in hemopoietic medicine |
| CN108864040A (en) * | 2018-08-28 | 2018-11-23 | 西安交通大学 | The hydrogen sulfide donor type compound of one kind -3- thione structure of dithiacyclopentene containing 1,2- and its reducing blood lipid application |
| CN111658665A (en) * | 2020-05-22 | 2020-09-15 | 南开大学 | Application of nano metal sulfide in preparation of drug for recovering aldol poisoning |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU588982A1 (en) * | 1976-04-26 | 1978-01-25 | Сочинский научно-исследовательский институт курортологии и физиотерапии | Method of treating diabetes mellitus |
-
2012
- 2012-09-29 CN CN201210378597.4A patent/CN103705537A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU588982A1 (en) * | 1976-04-26 | 1978-01-25 | Сочинский научно-исследовательский институт курортологии и физиотерапии | Method of treating diabetes mellitus |
Non-Patent Citations (1)
| Title |
|---|
| 关望等: ""气体信号分子硫化氢对高脂饲养大鼠肝脏脂代谢的调节作用"", 《解放军医学杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106176801A (en) * | 2015-05-06 | 2016-12-07 | 复旦大学 | Hydrogen sulfide purposes in struvite anemia medicine is treated in preparation |
| CN106176801B (en) * | 2015-05-06 | 2020-06-09 | 复旦大学 | Application of hydrogen sulfide in preparation of medicine for treating inflammatory anemia |
| CN106539818A (en) * | 2015-09-20 | 2017-03-29 | 复旦大学 | Hydrogen sulfide and its donor sodium hydrosulfide are preparing the purposes promoted in hemopoietic medicine |
| CN108864040A (en) * | 2018-08-28 | 2018-11-23 | 西安交通大学 | The hydrogen sulfide donor type compound of one kind -3- thione structure of dithiacyclopentene containing 1,2- and its reducing blood lipid application |
| CN111658665A (en) * | 2020-05-22 | 2020-09-15 | 南开大学 | Application of nano metal sulfide in preparation of drug for recovering aldol poisoning |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lo et al. | Effects of ingested fruiting bodies, submerged culture biomass, and acidic polysaccharide glucuronoxylomannan of Tremella mesenterica Retz.: Fr. on glycemic responses in normal and diabetic rats | |
| CN103705537A (en) | Applications of hydrogen sulfide and donor thereof sodium hydrosulfide in preparation of medicines used for treating lipid metabolism disorders | |
| Mahmoodi et al. | The effect of white vinegar on some blood biochemical factors in type 2 diabetic patients | |
| Uppu et al. | Insulin sensitization and resistance interrelationship revisited with a quantitative molecular model approach | |
| Enginyurt et al. | The role of pure honey in the treatment of diabetes mellitus | |
| CN1224383C (en) | Blood sugar reducing compound | |
| CN102423026A (en) | Micronized Stahlianthus involucratus jelly | |
| CN1301665C (en) | Blood fat-regulating liver-protecting health food | |
| CN104606451A (en) | Medicine-food dual-purpose composition for reducing postprandial blood sugar (IGT state) and preparation method | |
| CN104055947A (en) | Traditional Chinese medicine composition comprising grape extract products and preparation method thereof | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN106074671A (en) | U.S. rattan fruit leaf extract application in preparing hypoglycemic drug | |
| CN105535152B (en) | Application of loquat leaf total sesquiterpene extract | |
| WO2014018079A8 (en) | Method of treating hyperglycemic disorders using apolipoprotein aiv | |
| CN1429492A (en) | Balsam pear saccharide capable of regulating blood sugar and its production process | |
| Duška et al. | Intensive blood glucose control in acute and prolonged critical illness: endogenous secretion contributes more to plasma insulin than exogenous insulin infusion | |
| CN106146488B (en) | The Preparation method and use of the double-functional group berberinc derivate of 9- substitutions | |
| CN101073596A (en) | Alpha-glycosidase inhibitor, its extraction and use | |
| Fallah Huseini et al. | Protective effect of Citrullus colocynthis (L.) Schard. fruit extract on high glucose-induced neurotoxicity in PC-12 cells | |
| KR20190052972A (en) | Composition for improving intestinal microbial flora containing radish extract as an active ingredient | |
| CN102293817B (en) | Traditional Chinese medicine composition for reducing blood sugar and preparation method thereof | |
| CN103804524A (en) | Method for improving yield of heparin sodium | |
| Elbossaty | Hypoglycemic Influence of Phytochemical Compounds of Medicinal Plants and their Mechanism Action | |
| CN105770341A (en) | Preparation method of compound preparation for treating high blood pressure | |
| Rais et al. | Potential of S-allyl cysteine, a major bioactive component of garlic, as hypoglycemic and hypolipidemic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140409 |